Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 11, 2024 (GLOBE NEWSWIRE) — The global cell based assays market (세포 기반 분석 시장) was projected to attain US$ 20.2 billion in 2023. It is anticipated to garner a 6.4% CAGR from 2024 to 2034, and by 2034, the market is likely to attain US$ 40.4 billion. Cell-based assays, also known as cellular assays, are important instruments for assessing cell health, proliferation, viability, chemotaxis, invasion, and migration.

Cell-based screening is used in drug development and biomedical research to accurately measure off-target interactions, biochemical processes, biological activity, and cytotoxicity. Cell proliferation tests provide several advantages, including the ability to generate and facilitate physiologically meaningful and complicated data. Unlike traditional biochemical tests, cell-based assays are more physiologically relevant and capable of analyzing drug properties.

However, cell-based assay system procedures cannot yet handle both water-insoluble and water-soluble test materials. Furthermore, there is a risk of contamination in the reusable cell counting chamber, variances between users, and variations in hemocytometer filling rates.

Water-insoluble and water-soluble test materials, however, are not currently compatible with cell-based assay system methods. In addition, there is a chance that the reusable cell counting chamber may get contaminated, that user-to-user differences will occur, and that hemocytometer filling rates will vary. These are a few of the things impeding the expansion of the cell-based assays market.

Request for a Sample PDF of this Research Report: https://www.transparencymarketresearch.com/cell-based-assays.html  

Key Findings of the Market Report 

• The use of cell-based assays might enhance the drug development process by furnishing crucial biological data pertaining to drug action mechanisms, cellular survival, and off-target consequences.
• Any toxicity concerns that may surface in the latter phases of clinical trials can be mitigated by cell-based screening.
• High-throughput cell-based assay procedures test several chemicals under different circumstances at the same time, producing a lot of data.
• When discovering potential drug candidates early in the drug development process, this approach is effective.
• The results of cell-based assays are being used successfully by a number of academic institutions and commercial businesses to develop treatments for long-term illnesses.

Market Trends for Cell Based Assays 

• Cell viability, cytotoxicity, proliferation, apoptosis, signal transduction, reporter gene activity, enzyme activity, receptor occupancy, receptor binding, and complement-dependent cytotoxicity are among the biological and functional impacts that may be evaluated using cell-based assays (CDC).
• Depending on the variables that need to be measured, the signal that is read out might be radioactivity, luminescence, colorimetric, absorbance, or fluorescence. Plate readers, microscopes, and flow cytometers can all be used to measure these signals.
• In modern biomedical research, the use of 3D cell culture assay optimization has been growing. The complexities of in vivo systems and traditional 2D models are bridged by 3D cell cultures. The 3D method highlights how important it is to have sophisticated assay optimization techniques.

Global Market for Cell Based Assays: Regional Outlook 

• In 2023, North America acquired a significant share of the market. Throughout the projection period, the region is probably going to keep its top spot.
• One of the key elements boosting North America’s market share for cell-based assays is the increase in drug discovery research being carried out by academic institutions in partnership with pharmaceutical corporations.
• North America market expansion is also being aided by the rising incidence of chronic illnesses, including diabetes, osteoarthritis, cardiovascular disease, and cancer, particularly in the United States.
• According to a research issued by the American Heart Association in January 2022, every 40 seconds a person was diagnosed with myocardial infarction in the U.S. The concerning prevalence of the chronic illness is fueling the North American market’s rise.

Global Cell Based Assays Market: Competitive Landscape

In order to improve disease diagnosis, companies operating on a global basis are developing novel cell-based tests. The following companies are well-known participants in the global cell based assays market: 

• Danaher Corporation
• GE Healthcare Inc.
• Charles River Laboratories
• Lonza Group Ltd.
• Thermo Fisher Scientific Inc.
• Merck & Co.
• PerkinElmer Inc.
• Cell Signaling Technology, Inc.
• Becton, Dickinson and Company
• Promega Corporation

Key developments by the players in this market are: 

• The Aquios STEM system was unveiled by Beckman Coulter Life Sciences in May 2022 as an innovative approach to stem cell analysis. The system’s goal is to drastically reduce turnaround time by eliminating manual and prone-to-mistake procedures.
• PhenoVista Biosciences and Olympus partnered in June 2020 to provide 3D cell-based testing services that aid in drug discovery.
• Promega Corporation and FUJIFILM Cellular Dynamics collaborated to develop novel assays for cellular biology observation in a system that more closely resembles the behavior of real body cells in March 2022.
• Selvita unveiled a cell-based phenotypic test tool for drug discovery in February 2021. The platform may be used to evaluate new chemicals for possible applications in medicine.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=846&ltype=S

Global Cell Based Assays Market Segmentation

Product Type 

• Instruments
• Assay Kits
• Reagents & Consumables
• Software
• Services

Application

• Drug Discovery
• Basic Research
• Predictive Toxicology
• Others

End User 

• Pharmaceutical & Biotech Companies
• Academic Institutions
• Contract Research Organizations
• Others

Region 

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Have a Look at the Related Reports of the Healthcare Domain: 

• Contrast Media Market – The contrast media market is expected to reach US$ 7.8 billion by 2031 from US$ 4.9 billion in 2022. The market is expected to increase at a CAGR of 5.2% from 2023 to 2031.
• AI in Cancer Diagnostics Market – The global AI in cancer diagnostics market is projected to flourish at a CAGR of 11.2% from 2022 to 2031. As per the report published by TMR, a valuation of US$ 2.0 billion is anticipated for the market in 2031. As of 2023, the market for AI in cancer diagnostics is expected to close at US$ 955 million.
• In-vitro Colorectal Cancer Screening Tests Market – The global In-vitro colorectal cancer screening tests market is projected to grow at a CAGR of 7.1% from 2024 to 2034 and reach more than US$ 2.5 Billion by the end of 2034.
• Companion Diagnostic Tests in Oncology Market – The global companion diagnostic tests in oncology market (종양학 시장에서의 동반진단 테스트) is expected to grow at a CAGR of 9.5% from 2024 to 2034 and reach US$ 17.0 Billion by the end of 2034.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube